PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30307
Abstract: Class I phosphoinositide 3‐kinase (PI3K) signaling is a major pathway in human cancer development and progression. Among the four PI3K isoforms, PI3Kα and PI3Kβ are ubiquitously expressed, whereas PI3Kγ and PI3Kδ are found primarily in… read more here.
Keywords: hepatocellular carcinoma; pi3k; hcc; advanced hcc ... See more keywords
The use of peripheral CD3+γδ+Vδ2+ T lymphocyte cells in combination with the ALBI score to predict immunotherapy response in patients with advanced hepatocellular carcinoma: a retrospective study
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-024-05896-y
Abstract: Currently, there is a lack of effective indicators for predicting the efficacy of immunotherapy in patients with advanced hepatocellular carcinoma (HCC). This study aimed to investigate the expression and prognostic value of peripheral T lymphocyte… read more here.
Keywords: advanced hcc; advanced hepatocellular; hepatocellular carcinoma; patients advanced ... See more keywords
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?
Sign Up to like & getrecommendations! Published in 2019 at "Investigational New Drugs"
DOI: 10.1007/s10637-019-00760-0
Abstract: SummaryThe second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab,… read more here.
Keywords: advanced hcc; therapy advanced; therapy; line therapy ... See more keywords
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Sign Up to like & getrecommendations! Published in 2020 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2020.103167
Abstract: Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy has been explored in this disease in order to improve survival outcomes. Nowadays, scientific research is focusing especially on immune checkpoint inhibitors, in particular… read more here.
Keywords: hepatocellular carcinoma; immunotherapy; immunotherapy advanced; advanced hepatocellular ... See more keywords
Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of clinical and experimental hepatology"
DOI: 10.1016/j.jceh.2019.07.012
Abstract: Hepatocellular carcinoma (HCC) incidence and mortality have shown an unfavorable upward trend over the last two decades, especially in developed countries. More than one-sixth of the patients have advanced HCC at presentation. Systemic therapy remains… read more here.
Keywords: hepatocellular carcinoma; therapy; advanced hcc; systemic therapy ... See more keywords
Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-05828-x
Abstract: We studied the characteristics and survival of patients with sorafenib-treated HCC and impact of underlying etiology on outcomes. This retrospective multicenter study recruited patients with sorafenib-treated advanced HCC (12/2016 to 4/2023) till death or the… read more here.
Keywords: etiology; non viral; advanced hcc; well tolerated ... See more keywords
Camrelizumab: an investigational agent for hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on investigational drugs"
DOI: 10.1080/13543784.2022.2022121
Abstract: INTRODUCTION : Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits were limited, particularly for advanced HCC. However, recent treatments with PD-1/PD-L1 inhibitor monotherapy and its combination with other therapies,… read more here.
Keywords: hepatocellular carcinoma; camrelizumab investigational; camrelizumab; investigational agent ... See more keywords
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Sign Up to like & getrecommendations! Published in 2018 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyx180
Abstract: Chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC). On the basis of the results of two pivotal Phase III placebo-controlled studies, sorafenib is currently acknowledged worldwide as the standard… read more here.
Keywords: hepatocellular carcinoma; chemotherapy; treatment; sorafenib ... See more keywords
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Liver International"
DOI: 10.1111/liv.70264
Abstract: Intensive Care Unit (ICU) admission is usually denied to patients with advanced hepatocellular carcinoma (HCC) due to the perceived poor prognosis associated with both cirrhosis and liver cancer. However, immunotherapy based on immune checkpoint inhibitors… read more here.
Keywords: advanced hcc; care; intensive care; patients advanced ... See more keywords
Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy
Sign Up to like & getrecommendations! Published in 2024 at "Liver Cancer"
DOI: 10.1159/000539380
Abstract: Abstract Introduction: Macrovascular invasion (MVI) is a strong prognostic factor for advanced hepatocellular carcinoma (HCC). The current criteria for radiological assessment are unclear in evaluating the impact of MVI on systemic therapy. In this study,… read more here.
Keywords: mvi recist; mvi; mvi progression; advanced hcc ... See more keywords
Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0766-y
Abstract: BackgroundCurrently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherapy response… read more here.
Keywords: mre; stiffness; hcc stiffness; immunotherapy response ... See more keywords